Twist Bioscience's (TWST) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Twist Bioscience (TWST) has had its "sell (D-)" rating restated by Weiss Ratings, indicating ongoing concerns regarding its performance.
• The stock recently experienced a 5.4% increase, trading at $32.79, with a market capitalization of $1.98 billion and various analysts holding mixed ratings.
• Insider activity showed significant selling, with SVP Paula Green and CAO Robert F. Werner reducing their stakes, reflecting a 7.82% and 4.21% decrease in ownership, respectively.

Twist Bioscience (NASDAQ:TWST - Get Free Report)'s stock had its "sell (d-)" rating restated by investment analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

TWST has been the topic of a number of other reports. Evercore ISI dropped their price target on Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating on the stock in a research note on Tuesday. Cowen reissued a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Finally, Barclays cut their target price on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a research note on Thursday, October 2nd. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Twist Bioscience has an average rating of "Moderate Buy" and an average price target of $48.50.

Twist Bioscience Stock Up 5.4%

Twist Bioscience stock traded up $1.67 during midday trading on Wednesday, reaching $32.79. The stock had a trading volume of 2,438,969 shares, compared to its average volume of 1,812,695. The stock has a market capitalization of $1.98 billion, a P/E ratio of -22.61 and a beta of 2.38. The firm's fifty day simple moving average is $27.72 and its 200-day simple moving average is $32.84. Twist Bioscience has a 1-year low of $24.07 and a 1-year high of $55.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The company had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts expect that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Activity

In other Twist Bioscience news, SVP Paula Green sold 9,724 shares of Twist Bioscience stock in a transaction on Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $313,015.56. Following the transaction, the senior vice president directly owned 114,678 shares in the company, valued at approximately $3,691,484.82. The trade was a 7.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Robert F. Werner sold 2,041 shares of the business's stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $65,699.79. Following the completion of the transaction, the chief accounting officer directly owned 46,413 shares of the company's stock, valued at approximately $1,494,034.47. This represents a 4.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 58,851 shares of company stock worth $1,859,894 in the last three months. 3.01% of the stock is currently owned by corporate insiders.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently made changes to their positions in TWST. GAMMA Investing LLC lifted its position in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after purchasing an additional 303 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock worth $85,000 after purchasing an additional 302 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Twist Bioscience in the second quarter valued at about $97,000. Bayforest Capital Ltd grew its stake in shares of Twist Bioscience by 49.3% during the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock valued at $191,000 after buying an additional 1,604 shares during the last quarter. Finally, Pallas Capital Advisors LLC acquired a new stake in Twist Bioscience during the 1st quarter worth about $201,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.